Selective JAK1 inhibitor and selective Tyk2 inhibitor patents

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 10, 2012, Pages 1233-1249

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

IL 12; IL 17; IL 23; IL 6; JAK1; JAK1 inhibitor; JAK2; JAK3; Multiple sclerosis; Rheumatoid arthritis; STATs; Tyk2; Tyk2 inhibitor

Indexed keywords

AC 430; BMS 911543; CEP 33779; GLPG 0634; JANUS KINASE 1; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3 INHIBITOR; JANUS KINASE INHIBITOR; PROTEIN KINASE TYK2; PROTEIN KINASE TYK2 INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; R 723; RUXOLITINIB; TOFACITINIB; UNCLASSIFIED DRUG;

DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MANUFACTURE; MULTIPLE SCLEROSIS; MYELOFIBROSIS; PATENT; PUBLISHING; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; DRUG DISCOVERY; HUMANS; JANUS KINASE 1; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TYK2 KINASE;

EID: 84866724568     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.723693     Document Type: Review

References (66)

1. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293-322
2. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003; 3(11):900-11
3. Ihle J, Kerr IM. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 1995;11:69
4. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000;95:19-29
5. Verma A, Kambhampati S, Parmar S, Platanias LC. Jak family of kinases in cancer. Cancer Metastasis Rev 2003; 22:423-34
6. Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010;22(3):330-5.
7. Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev 2011;25(5):229-37
8. Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690, 550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53(24):8468-84.
9. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115(15):3109-17.
10. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012;36(4):542-50
11. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012;36(4):503-14
12. Kiss R, Sayeski PP, Keser GM. Recent developments on JAK2 inhibitors: a patent review. Expert Opin Ther Pat 2010;20(4):471-95.
13. Quintas-Cardama A, Verstovsek S. New JAK2 inhibitors for myeloproliferative neoplasms. Expert Opin Investig Drugs 2011;20(7):961-72
14. Wilson LJ. Recent patents in the discovery of small molecule inhibitors of JAK3. Expert Opin Ther Pat 2010;20(5):609-23.
15. Shide K, Kameda T, Markovtsov V, et al. R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm. Blood 2011;117(25):6866-75
16. Belli B, Brigham D, Dao A, et al. AC430, a Potent JAK2 inhibitor, Provides protection in multiple inflammatory and autoimmune disease models. [abstract]. Arthritis Rheum 2010;62(Suppl 10):269
17. Ambit Biosciences Corp. Hydrobromide Salts of a Pyrazolylaminoquinazoline. US20120053195; 2012
18. Stump KL, Lu LD, Dobrzanski P, et al. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther 2011;13(2):R68
19. Purandare AV, McDevitt TM, Wan H, et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia 2012; 26(2):280-8
20. Schenkel LB, Huang X, Cheng A, et al. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors. J Med Chem 2011;54(24):8440-50
21. Thoma G, Nuninger F, Falchetto R, et al. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. J Med Chem 2011;54(1):284-8
22. Soth M. Kinase research at Roche Nutley, presentation at Protein Kinase Signalling Success: 5th SCI RSC Symposium on kinase inhibitor design; Cambridge: 2012
23. Hoock T, Hogan J, Mahajan S, et al. VX-509, An orally Available Janus Kinase 3 (JAK3) specific inhibitor, showed robust activity in pre-clinical models of aberrant immune/inflammatory function. [abstract]. Arthritis Rheum 2011;63(Suppl 10):1136
24. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998;93(3):373-83
25. Lupardus PJ, Skiniotis G, Rice AJ, et al. Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6R? cytokine receptor complex, and the receptor-Jak1 holocomplex. Structure 2011;19(1):45-55
26. Shimoda K, Tsutsui H, Aoki K, et al. Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood 2002;99(6):2094-9
27. Seto Y, Nakajima H, Suto A, et al. Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice. J Immunol 2003;170(2):1077-83
28. Ishizaki M, Akimoto T, Muromoto R, et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J Immunol 2011;187(1):181-9
29. Grebien F, Kerenyi MA, Kovacic B, et al. Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood 2008;111(9):4511-22
30. Drachman JG, Millett KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem 1999; 274(19):13480-4
31. Suzuki K, Nakajima H, Saito Y, et al. Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice. Int Immunol 2000;12(2):123-32
32. Fleischmann RM, Genovese MC, Gruben D, et al. Safety and Efficacy After 24 Week (wk) Dosing of the Oral JAK Inhibitor CP-690, 550 (CP) as Monotherapy in Patients (pts) with Active Rheumatoid Arthritis (RA). Arthritis Rheum 2009;60(Suppl 10): 1924
33. Keystone E, Taylor P, Genovese M, et al. 12-Week Results of a Phase IIb Dose-Ranging Study of LY3009104 (INCB028050), an Oral JAK1/JAK2 Inhibitor, in Combination with Traditional DMARDs in Patients with Rheumatoid Arthritis. EULAR abstract LB0005 2012. Available from: http://www.incyte.com/sites/default/ files/JAK% 2012%20EULAR%20Presentation% 204%20%20Jun%202012%20MASTER %20COPY%20sec-0.pdf).
34. Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients NCT01384422 (June 2011). Avaialble from http://clinicaltrials.gov
35. Ludwig Institute For Cancer Research Ltd. Inhibitors Of Constitutively Active Janus Kinases And Uses Thereof. WO2010141062; 2010
36. Genentech, Inc. Triazolopyridine JAK Inhibitor Compounds And Methods. WO2009155551; 2009
37. Genentech, Inc. Triazolopyridine JAK Inhibitor Compounds And Methods. WO2009155565; 2009
38. Genentech, Inc. Pyrazolopyrimidine JAK Inhibitor Compounds And Methods. WO2010051549; 2010
39. F. Hoffmann-La Roche AG. Tricyclic Heterocyclic Compounds, Compositions And Methods Of Use Thereof. WO2011086053; 2011
40. F. Hoffmann-La Roche AG. Tricyclic Pyrazinone Compounds, Compositions And Methods Of Use Thereof As Janus Kinase Inhibitors. WO2012085176; 2012
41. Kulagowski JJ, Blair W, Bull RJ, et al. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors. J Med Chem 2012;55(12):5901-21.
42. Zak M, Mendonca R, Balazs M, et al. Discovery and optimization of C-2 Methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. J Med Chem 2012;55(13): 6176-93.
43. Abbott Laboratories Novel Tricyclic Compounds. WO2009152133; 2009
44. Abbott Laboratories Novel Tricyclic Compounds. WO2011068881; 2011
45. Galapagos NV 5-Phenyl-[1, 2, 4]Triazolo [1, 5-a]Pyridin-2-yl Carboxamides As JAK Inhibitors. WO2010149769; 2010.
46. Galapagos NV [1, 2, 4] Triazolo [1, 5-a] Pyridines As JAK Inhibitors. WO-2010010184; 2010
47. Menet C. First selective JAK1 inhibitor: GLPG0634 from hit to Proof of Concept at Protein Kinase 2012, Cambridge, May 2012. Available from: http://www.soci.org/News/~/media/Files/Conference%20Downloads/Protein% 20Kinase%202012/Christel-Menet-Presentation.ashx).
48. Vanhoutte FP, Mazour M, Namour N, et al. Efficacy and safety of GLPG0634, a selective JAK1 inhibitor. after short-term treatment of rheumatoid arthritis; results of a phase IIA trial. Ann Rheum Dis 2012;71(Suppl3):145.
49. Abbott Inc Abbott and Galapagos Announce Global Collaboration for Novel Oral Therapy, GLPG0634, in Phase II to Treat Autoimmune Diseases Press: Release 29 February 2012
50. Incyte Corp. N-(Hetero)arylpyrrolidine derivatives of Pyrazol-4-Yl-pyrrolo[2, 3-d] pyrimidines and pyrrol-3-yl-pyrrolo[2, 3-d]pyrimidines as janus kinase inhibitors. WO-2010135650; 2010
51. Incyte Corp. Piperidin-4-ylazetidine Derivatives as JAK1 Inhibitors. WO2011112662; 2011
52. Exelixis, Inc. Phthalazine Derivatives As Jak1 Inhibitors. WO2012037132; 2012
53. Bayer Schering Pharma AG. New phenyl-pyrimidin-2-yl-amine compounds are tyrosine kinase 2 inhibitors useful for treating e.g. rheumatoid arthritis, Crohn's disease, asthma, multiple sclerosis, adult respiratory distress syndrome, allergic alveolitis and uveitis. DE102009015070A1; 2010 49.
54. Sareum Ltd. Available from: http://www. sareum.co.uk/base/images/pdfs/ Sareum-SKIL-TYK2-Mar12.pdf.
55. Schering AG. CHK-, PDK-and AKT-Inhibitory Pyrimidines, Their Production And Use As Pharmaceutical Agents. WO2004048343; 2004
56. F. Hoffmann-La Roche AG. Imidazopyridine And Purine Compounds, Compositions And Methods Of Use. WO2011113802; 2011
57. F. Hoffmann-La Roche AG. Azabenzothiazole Compounds, Compositions And Methods Of Use. WO2012035039; 2012
58. F. Hoffmann-La Roche AG. Pyrazolopyridines And Pyrazolopyridines And Their Use As Tyk2 Inhibitors. WO2012066061; 2012
59. Cellzome Ltd. Triazolopyridines As Tyk2 Inhibitors. WO2012000970; 2012
60. Cellzome Ltd. Pyridine Compounds And Aza Analogues Thereof As Tyk2 Inhibitors. WO2012062704; 2012
61. Wu Y, Chen J, Li YH, et al. Treatment of psoriasis with interleukin-12/23 monoclonal antibody: a systematic review. Eur J Dermatol 2012;22(1): 72-82
62. Geremia A, Jewell DP. The IL-23/IL-17 pathway in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2012;6(2):223-37
63. Malerich JP, Lam JS, Hart B, et al. Diamino-1, 2, 4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3. Bioorg Med Chem Lett 2010;20(24):7454-7
64. Vertex Pharmaceuticals Phase 2a Study of Selective Oral JAK3 Inhibitor VX-509 Showed Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis, press release 6 September 2011. First report of clinical efficacy of a selective JAK3 inhibitor.
65. Greenwald M, Fidelus-Gort R, Levy R, et al. A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis. American College of Rheumatology 2010 Annual Meeting, Atlanta, GA, USA. Arthritis Rheum 2010;62(Suppl 10):abstract 2172
66. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum 2009;60(7):1895-905